Biktarvy for the treatment of HIV infection: Progress and prospects
E De Clercq, Z Zhang, J Huang, M Zhang… - Biochemical Pharmacology, 2023 - Elsevier
Abstract Bictegravir (BIC), a second-generation integrase strand-transfer inhibitor (INSTI)
with high resilience to INSTI-resistance mutations, is integrated as a key component of …
with high resilience to INSTI-resistance mutations, is integrated as a key component of …
Real-world discontinuations due to neuropsychiatric symptoms in people living with HIV treated with second-generation integrase inhibitors: a systematic review
I Perez-Valero, D Corona, N Martinez… - Expert Review of Anti …, 2023 - Taylor & Francis
Introduction Second-generation integrase strand transfer inhibitors such as bictegravir (BIC)
and dolutegravir (DTG) are the standard of care for starting therapy in people living with HIV …
and dolutegravir (DTG) are the standard of care for starting therapy in people living with HIV …
Twelve‐month effectiveness and safety of bictegravir/emtricitabine/tenofovir alafenamide in people with HIV: Real‐world insights from BICSTaR cohorts
S Esser, J Brunetta, A Inciarte, I Levy… - HIV …, 2024 - Wiley Online Library
Background Real‐world evidence is an essential component of evidence‐based medicine.
The aim of the BICSTaR (BICtegravir Single Tablet Regimen) study is to assess …
The aim of the BICSTaR (BICtegravir Single Tablet Regimen) study is to assess …
Comparative effectiveness of switching to bictegravir from dolutegravir-, efavirenz-, or raltegravir-based antiretroviral therapy among individuals with HIV who are …
Background We aimed to determine the effectiveness of switching to bictegravir in
maintaining an undetectable viral load (< 50 copies/mL) among people with HIV (PWH) as …
maintaining an undetectable viral load (< 50 copies/mL) among people with HIV (PWH) as …
Bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in treatment-naïve and treatment-experienced people with HIV: 12-month virologic effectiveness and safety …
Y Yokomaku, K Teruya, D Watanabe, T Endo… - PloS one, 2025 - journals.plos.org
BICSTaR (BICtegravir Single Tablet Regimen) is an ongoing, observational cohort study
assessing the virologic effectiveness and safety of bictegravir/emtricitabine/tenofovir …
assessing the virologic effectiveness and safety of bictegravir/emtricitabine/tenofovir …
Effectiveness, safety and discontinuation rates of bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) in people with HIV using real-world data: a systematic …
I Chivite, L Berrocal, E de Lazzari… - Journal of …, 2024 - academic.oup.com
Background The use of bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) is
based on the results of robust clinical trials. Objectives To assess the effectiveness and …
based on the results of robust clinical trials. Objectives To assess the effectiveness and …
[HTML][HTML] Real-life experience with bictegravir/emtricitabine/tenofovir alafenamide in Turkey
U Balcı, Ü Üser, A Tahmaz, FS Yildirim - Cureus, 2023 - ncbi.nlm.nih.gov
Abstract Introduction: Single-tablet regimens (STRs) can increase treatment success and
even improve the quality of life of human immunodeficiency virus (HIV) patients. In this study …
even improve the quality of life of human immunodeficiency virus (HIV) patients. In this study …
Clinical efficacy, safety, and subjective experience based on ePRO in HIV‐infected individuals administered Bictegravir/Emtricitabine/Tenofovir Alafenamide in …
L Kong, X **e, Y Fu, L Gan, X Yang… - Immunity …, 2023 - Wiley Online Library
Background Prospective studies examining long‐term therapeutic outcomes of the
Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) regimen in human …
Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) regimen in human …
Profile of Newly Diagnosed Patients with HIV Infection in North-Eastern Romania
Background and Objectives: Human immunodeficiency virus infection and the acquired
immunodeficiency syndrome (HIV/AIDS) pandemic are unquestionably the most serious …
immunodeficiency syndrome (HIV/AIDS) pandemic are unquestionably the most serious …
Twelve-month effectiveness and safety of bictegravir/emtricitabine/tenofovir alafenamide in people with HIV from the Canadian cohort of the observational BICSTaR …
A Wong, J Brunetta, J De Wet, K Logue, H Loemba… - Medicine, 2024 - journals.lww.com
Abstract The BICSTaR (BICtegravir Single Tablet Regimen) study is investigating the
effectiveness and safety of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in …
effectiveness and safety of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in …